Skip to main content
Clinical Trials/NCT05216029
NCT05216029
Active, Not Recruiting
N/A

Study of Efficacy of Oncology Dashboard in Improving Operational Efficiency and Patient Outcomes

M.D. Anderson Cancer Center1 site in 1 country92 target enrollmentOctober 1, 2015

Overview

Phase
N/A
Intervention
Informational Intervention
Conditions
Sarcoma
Sponsor
M.D. Anderson Cancer Center
Enrollment
92
Locations
1
Primary Endpoint
Time to complete medical oncology review (oncology workflow)
Status
Active, Not Recruiting
Last Updated
3 months ago

Overview

Brief Summary

This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their care more efficiently. The oncology dashboard tool may help patients understand the disease better and may help improve the efficiency of their medical care.

Detailed Description

PRIMARY OBJECTIVE: I. To compare the changes in oncology workflow times from baseline to follow up visits between intervention (follow-up visit with oncology dashboard tool) and control (follow-up visit without oncology dashboard tool) groups. SECONDARY OBJECTIVES: I. To compare the changes in radiology workflow times from baseline to follow up visits between intervention (follow-up visit with oncology dashboard tool) and control (follow-up visit without oncology dashboard tool) groups. II. Assess and compare the proportion of patients who correctly indicate the changes in tumor size while on therapy at the baseline and at the follow-up visit (with the oncology dashboard tool). IIa. Compare the change in proportion of patients who correctly indicate the changes in tumor size while on therapy from baseline to follow-up visit between intervention and control groups. III. Assess the patient's satisfaction with physician communication during the clinic visit and with the current treatment plan at each visit for each group. IV. Assess changes in the radiology report quality with the following measures (all changes will be compared between intervention and control groups): IVa. Whether or not the current study was compared to the imaging study that was performed at the start of current therapy. IVb. The number of time points reviewed by the radiologist. IVc. The time interval between the earliest study reviewed and the current study. IVd. Percentage of target lesions measured and listed in the radiology report. V. In patients who have stable disease or mildly progressive disease at the time of the baseline assessment, assess the impact of patient understand on the decision to continue and discontinue therapy. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard. GROUP II: Patients receive standard of care.

Registry
clinicaltrials.gov
Start Date
October 1, 2015
End Date
February 2, 2027
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with sarcoma on active chemotherapy/targeted therapy
  • Patients must have stable to mildly progressive disease or better on baseline assessment
  • Baseline measurement and follow-up measurement have to be performed on the same treatment for consistency. If patients with progressive disease are included into the study at baseline, follow-up measurement will be on a different treatment. Invariable, initiation of a new treatment, in the setting of progressive disease, lengthens oncology workflow which would affect the post measurement
  • Patients must have been on the same treatment for at least 6 weeks
  • Patients must have at least 3 prior imaging studies of the same body part/tracked lesion/area of interest separated by 6 weeks or more between studies
  • Patients should be continuing same therapy for the next 6-8 weeks
  • Patients must have plan for follow-up with imaging studies at MD Anderson Cancer Center (MDACC) while on therapy
  • Patients who are receiving therapy outside of MDACC but having their follow-up imaging at MDACC are eligible
  • \>= 18 years of age

Exclusion Criteria

  • Expected survival of less than 8 weeks
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 4
  • Non- English-speaking patients and patients with cognitive impairment who cannot complete the questionnaire

Arms & Interventions

Group I (oncology dashboard)

Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.

Intervention: Informational Intervention

Group I (oncology dashboard)

Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.

Intervention: Questionnaire Administration

Group II (standard of care)

Patients receive standard of care.

Intervention: Best Practice

Group II (standard of care)

Patients receive standard of care.

Intervention: Questionnaire Administration

Outcomes

Primary Outcomes

Time to complete medical oncology review (oncology workflow)

Time Frame: through study completion, an average of 1 year

Study Sites (1)

Loading locations...

Similar Trials

Completed
N/A
Electronic Symptom Monitoring Intervention for Hospitalized Patients With CancerCancer
NCT03396510Massachusetts General Hospital390
Completed
N/A
A Computer-Based System for Symptom Reporting in Patients With Cancer Undergoing TreatmentCaregiverMalignant Neoplasm
NCT03979846Thomas Jefferson University20
Completed
N/A
Patient Portal and Navigation Program in Providing Information for Asian American Cancer PatientsCaregiverMalignant NeoplasmPhysicianStage I Colorectal Cancer AJCC v8Stage I Liver CancerStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage II Liver CancerStage II Lung Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Colorectal Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIC Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Liver CancerStage III Lung Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8
NCT03867916University of California, San Francisco106
Completed
N/A
validation study of cancer-related diagnosis and outcomes on Japanese electronic medical recordsCancer
JPRN-UMIN000039345Kurashiki Central Hospital, Kurashiki450
Completed
Phase 1
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).Head and Neck Squamous Cell Carcinoma
NCT03022409AstraZeneca21